What is a Hybridoma?

Hybridomas are the result of a fusion between an antibody producing spleen cell and an immortal myeloma cell. 

Introduction

Hybridoma technology introduced one of the earliest reliable methods for producing monoclonal antibodies. A hybridoma forms when an antibody-producing B cell is fused with a long-lived myeloma cell, creating a stable line that continuously secretes identical antibodies. This concept remains foundational in immunology and antibody development.

Understanding What Hybridoma Cells Are

Hybridomas are the result of a fusion between an antibody-producing spleen cell and an immortal myeloma cell. The B cell contributes natural antigen specificity, while the myeloma cell supplies continuous growth. Together, these properties allow hybridomas to produce monoclonal antibodies in a consistent and renewable manner. Hybridomas helped establish the first scalable approach for generating targeted antibodies that retain the genetic identity of a single B cell clone.

Why Hybridoma Technology Remains Important

Hybridoma systems continue to play a role in research and development because they support:

Stable antibody secretion

Once a hybridoma line is established, antibody output remains uniform.

Defined genetic origin

All antibodies produced originate from one B cell, supporting reproducibility across experiments and batches.

Long-term preservation

Hybridomas can be expanded, stored, and revived without losing their antibody-producing capacity.

These characteristics maintain the relevance of hybridoma platforms, even as newer sequencing and recombinant technologies emerge.

How Hybridoma Cells are Created

The creation of hybridomas involves several coordinated steps that preserve antibody specificity while enabling long-term production.

Immunization and B Lymphocyte Isolation

Hybridoma production begins by immunizing laboratory animals, typically mice, with the antigen of interest. This antigen stimulates the mouse’s immune system to produce B lymphocytes that generate antibodies targeting the specific antigen. After a series of immunizations, the spleen (rich in activated B cells) is removed for isolation of the B lymphocytes that now carry genetic information to produce antigen-specific antibodies.

Fusion of B Cells with Myeloma Cells

Isolated B lymphocytes are then fused with immortalized myeloma cells, which are cancerous plasma cells with a high proliferation capacity. This fusion process uses polyethylene glycol (PEG) to promote the merging of cell membranes, creating hybrid cells or "hybridomas." The myeloma cells provide longevity, while the B lymphocytes contribute the antibody-producing capacity. The hybridoma cells that form are effectively immortal, allowing for indefinite production of a consistent, highly specific monoclonal antibody.

Selection and Screening

Hybridoma cells are cultured in a selective medium (HAT medium) to filter out unfused cells. Only hybridomas—those with both B cell and myeloma cell properties—survive, as they possess both the antibody-coding genes from B cells and the longevity from myeloma cells. Once selected, the hybridomas are screened to identify those producing the desired antibody, which is subsequently purified for applications in research and therapeutics.

Benefits of Hybridoma Technology

Hybridoma-derived monoclonal antibodies offer several advantages for research and diagnostics.

• Hybridoma-derived antibodies are highly specific 

• Reproducible and scalable, ensuring consistency across large batches 

• Unlimited production of monoclonal antibodies 

• Useful for highly sensitive and specific assays 

• Purity of antigen or immunogen is not a prerequisite 

• Not labor-intensive as in vitro antibody generation techniques uses immune libraries 

• Once the hybridoma line is established, the cost per antibody unit decreases 

• Widely used in both diagnostic and therapeutics¹

Challenges in Hybridoma Technology

Despite its value, hybridoma technology presents several challenges.

• Time-consuming, taking 6-9 months 

• Expensive and requires considerable effort in production 

• Unsuitable for producing antibodies against small peptides and fragment antigens 

• High contamination risks 

• Currently only developed for mice and rats, but researchers are working to develop antibodies of human origin  

• Low viable efficiency of cells is quite low 

• Potential cross-contamination or infection in humans  

• Fusion of human lymphocyte and mouse myeloma cells may result in the production of unstable fused cells¹

These challenges have encouraged the adoption of sequencing-based and recombinant alternatives in many workflows.

Related: What is Hybridoma Technology?

Hybridoma Technology in Modern Antibody Workflows

Hybridomas continue to support:

• Production of monoclonal antibodies for immunoassays

• Early-stage discovery and antigen specificity studies

• Development of reference materials

• Retrieval of parental sequences for downstream engineering

• Characterization of immune responses in model organisms

Although other technologies have emerged, hybridomas remain a reliable source of natural antibody sequences.

The Future of Hybridoma Technology

Advances in genome-editing tools, like CRISPR, offer the potential to improve the precision of human antibody production, reducing the need for traditional animal-derived hybridomas and potentially more diverse and human-compatible mAb therapies. As hybridoma technology continues to evolve, we can expect to see further improvements in monoclonal antibody production efficiency, specificity, and safety—transforming hybridoma technology from a classic method to a modern powerhouse in therapeutic antibody production.

References:

1. Mitra, S., & Tomar, P. C. (2021). Hybridoma technology; advancements, clinical significance, and future aspects. Journal of Genetic Engineering & Biotechnology, 19, 159. https://doi.org/10.1186/s43141-021-00264-6